Lv4
768 积分 2023-08-01 加入
Fulzerasib plus cetuximab in first-line KRAS-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
3个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
3个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
3个月前
已完结
An Immunosuppressive Antibody–Drug Conjugate
4个月前
已完结
Opportunities and challenges of targeting cGAS–STING in cancer
5个月前
已完结
Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer
5个月前
已完结
An orally available non-nucleotide STING agonist with antitumor activity
5个月前
已完结
E7766, a Macrocycle‐Bridged Stimulator of Interferon Genes (STING) Agonist with Potent Pan‐Genotypic Activity
5个月前
已完结
The complex patent situation regarding antibody Fc engineering
5个月前
已完结
A next-generation STING agonist MSA-2: From mechanism to application
5个月前
已完结
皖公网安备34019202002308
